Conversion from a basal-bolus insulin regimen to a GLP-1RA and basal insulin in type 2 diabetes
Many patients at the Advocate Aurora Family Medicine clinic are managed on basal bolus insulin. This regimen can be very complex and difficult to manage for many patients. In addition is it associated with many side effects such as hypoglycemia and weight gain. A newer regimen recently incorporated in the ADA guidelines for the management of T2DM is the combination of a glucagon-like peptide-1 receptor agonist (GLP-1RA) plus basal insulin. GLP-1 is an incretin hormone which increases insulin secretion and decreases glucagon secretion in a glucose dependent manner, lowering the risk for hypoglycemia. GLP-1 also slows gastric emptying and improves satiety leading to potential weight loss. GLP-1RA are generally well tolerated, with their most prominent negative effect being GI side effects. This presentation will review the two regimens and a retrospective case series performed at the Advocate Aurora Family Medicine clinic on patients that were successful and unsuccessful in converting from basal bolus insulin to a GLP-1 receptor agonist and basal insulin.
This course is intended for Family Practice
At the end of this session, learners should be able to:
- Identify the risks and benefits of transitioning a patient from basal bolus insulin to a regimen including a GLP-1 receptor agonist and basal insulin.
- Recognize if a patient would be a candidate for GLP-1 therapy.
Course Director: Dennis Baumgardner, MD; AdvocateAurora Health
Kelsey Gardetto, PharmD; AdvocateAurora Health
Christopher Klink, PharmD, BCPS; AdvocateAurora Health
Thomas Disworth, PharmD, BCPS, AQ-ID; AdvocateAurora Health
It is the policy of Aurora Health Care Office of Continuing Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored education activities. All participating faculty, course directors, and planning committee members are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. All faculty and planning committee members have attested that their financial relationships do not affect their ability to present well-balanced evidence-based content for this activity. Specific disclosure information for each course faculty will be shared with the audience prior to the faculty’s presentation.
In the process of collecting disclosures. All disclosures will be made in advance of the activity.
- 0.25 AMA PRA Category 1 Credit™Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 0.25 AttendanceAttendance Credit